NascaCell IP GmbH merged with NascaCell Technologies AG(05/08/2006) The merger between the biotechnology companies NascaCell IP GmbH and NascaCell Technologies AG has been registered under NascaCell Technologies AG with the Munich courts (Handelsregister). Dr. Ernst Böhnlein as CEO and Dr. Michael Blind as CSO are ...
NascaCell IP GmbH announces management change and closure of new financing round(03/09/2006) NascaCell IP GmbH announced the appointment of Dr. Michael Blind to the position of CEO (Chief Executive Officer). Prior to his promotion, Dr. Blind was responsible for the research and development activities at NascaCell. Dr. Blind, who is also ...
Boehringer Ingelheim and NascaCell announce research collaboration on aptamers(02/18/2005) Boehringer Ingelheim and NascaCell announced that they have entered into a research collaboration on aptamer based target validation and drug discovery. Under the agreement, NascaCell will provide Boehringer with custom aptamers for therapeutic ...
NascaCell announces an aptamer distribution agreement in Japan with GE Healthcare(10/25/2004) NascaCell IP GmbH announced today that it has entered into a collaboration agreement with GE Healthcare to market aptamers for target validation and drug discovery in Japan. The agreement is part of NascaCell's business strategy to make aptamers ...
NascaCell announces a collaboration agreement with Aventis(09/14/2004) Munich. NascaCell announced that it has entered into a collaboration with Aventis. Under a framework agreement NascaCell will provide Aventis with access to its proprietary aptamer technology. Aventis is a global pharmaceutical company with a ...
Top
